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ABSTRACT
Salbutamol  sulphate  metered  dose  inhaler  formulations  were  developed  with  chlorine  free,  non-CFC  propellant 
Tetrafluoroethane.  Suspension  formulations  were  prepared  with  4  mg  of  oleic  acid  as  the  surfactant  and  varying 
proportions of ethanol as the co-solvent. Developed formulations were subjected to various qualitative and quantitative 
tests to ensure proper stability of the final package. In-vitro drug deposition studies using Twin impinger and Anderson 
cascade impactor indicated a net respirable fraction of 34-36.7% for the optimized formulation. Stability studies showed 
that the formulation was stable for a period of three months under all storage conditions. Effects of different adaptors and 
metering valve designs on the performance of the formulation were also checked. Comparison of optimized formulation 
with  commercial  CFC  and  non-CFC  formulations  exhibited  equivalent  performance  characteristics.  Thus, 
Tetrafluoroethane  proved  to  be  an  environment  friendly  substitute  for  CFC  propellants  in  metered  dose  inhalation 
formulations.
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INTRODUCTION
A wide variety of population around the globe is affected by 
Asthma, a chronic respiratory disease of lungs. Although the 
therapeutic agent for asthma could be delivered by oral and 
injectable routes, faster action is achieved via the pulmonary 
route.  The  pulmonary  route  of  treatment  offers  many 
advantages like the  vast permeability of lungs and profuse 
vasculature  of  airways.  The  convenience  of  self-
administering the dose of drug accurately and quickly to the 
pulmonary  region  has  made pressurized  metered  dose 
inhalers the treatment of choice for asthma. 
[1]
Drugs  in  aerosol  formulations  are  either  dissolved  or 
suspended in the propellant for delivery to the lungs.
[2] Most 
of the metered dose inhalers are marketed as suspensions due 
to  their  wide  applicability  and  stability.  Moreover,  the 
number of drugs that are freely soluble in the propellant and 
co-solvent  mixtures  are  limited.  Typically,  suspension 
formulations  contain  a  mixture  of  micronized  drug,  a 
surfactant,  a  co-solvent  and  propellant.  In  suspension 
formulations, particle size of the drug is critical because it 
influences pulmonary deposition and also affects suspension 
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stability.  Optimum  particle  size  for  deposition  into  the 
pulmonary system is less than or equal to 5 µm and not more 
than 10 µm.
[3]
Salbutamol  Sulphate,  a  β-2  receptor  agonist  has  been 
administered  by  oral  and  inhalation  routes  for  asthma 
treatment. Standard dose of the drug is 2 to 4 mg and given to 
the  patient  3  to  4  times  a  day.
[4] The  inhalable  dose  of 
Salbutamol Sulphate is found to be lower than the oral dose 
because  of  evasion  of  presystemic  metabolism  and  direct 
delivery to lungs.
Chlorofluorocarbons  were  the  propellants  of  choice  for 
marketed inhalation aerosols. Although CFC’s were stable in 
lower  atmosphere  of  earth,  in  the  stratosphere,  slow 
degradation by solar radiation resulted in damage to ozone 
layer by formation of free radicals of chlorine.
[5] Destruction 
of ozone layer allowed increased transmission of ultraviolet 
radiation  to  earth’s  surface.  Hence,  the  use  of 
Chlorofluorocarbon  propellants  was  halted  as  per  the 
Montreal  protocol,  1987.
[6] Non-chlorofluorocarbons  like 
Tetrafluoroethane (HFA-134a) with the absence of chlorine 
atoms  and  zero  ozone  depleting  potential  can  effectively 
substitute  the  conventional  CFC  propellants.  Hence,  the 
objective  of  present  work  was  to  develop  Salbutamol 
sulphate  metered  dose  inhalation  suspension  formulations 
using non-CFC propellant Tetrafluoroethane for treatment of 
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MATERIALS AND METHODS
Materials
Micronized  Salbutamol  Sulphate  was  obtained  from  Cipla 
Ltd,  Mumbai.  Anodized  aluminium  Canisters  of  20  ml 
capacity  were  procured  from  Midas  Health  care,  Mumbai, 
India. Metered Dose valves of 63 µl capacity were provided 
by Valois Ltd, India. Propellant HFC-134a was obtained as a 
gift  sample  from Stallion  enterprises,  Mumbai,  India.  All 
other  reagents  and  chemicals  used  in  the  study  were  of 
analytical grade. 
Preparation  of  Salbutamol  sulphate  metered  dose 
inhalers using Tetrafluoroethane
Salbutamol sulphate MDI formulations were prepared using 
pressure  filling  technique.  The  required  quantity  of  Oleic 
acid and 95% ethanol were mixed properly in an enclosed 
vessel  and  maintained  in  an  ice-bath.  Salbutamol  sulphate 
was  added  into  each  canister  and  they  were  immediately 
crimped  using  Brassomatic  aerosol crimping machine  with 
20  mm  neck  diameter  crimping  collet.  Tetrafluoroethane 
(HFC-134a)  cylinder  was  kept  in an  inverted  position  and 
connected to Brassomatic aerosol filling machine. The valve 
was  opened  and  propellant  was  allowed  to  flow  into  the 
storage cylinder upto the desired level. The valve was then 
closed  tightly.  Nitrogen  cylinder  valve  was  opened  and 
pressure was built upto 15 lbs/kg cm
2. The valve was closed 
after achieving the desired pressure. The canisters were kept 
in  sonicator  for  half  an  hour  to  achieve  a  uniform,  well 
dispersed suspension. The whole operation was carried out at 
a temperature maintained to about 20-21°C due to the ease in 
propellant handling and humidity below 40% RH to avoid 
breakdown of propellant. 
Quality control tests on Metered dose inhalers
Qualitative tests based on aerosol performance
 Spray  pattern: The  spray  delivered  from  the 
formulations was impinged onto a glass plate containing 
activated silica gel-dye mixture. The MDI was held at a 
distance of 3 cm from the plate. The spots thus formed 
as  a  result  of  spray  testing  were  observed  under  long 
wave U.V light for their characteristics. 
[7]
 Particle  size  distribution: Binocular  Labomed  vision 
2000  TM  microscope  was  used  for  particle  size 
determination.  Metered  dose  inhalers  under  evaluation 
were sprayed on a glass slide. The slide was rinsed with 
CCl4 to prevent the excipient particles from interfering 
with the measurement of drug particles. After sufficient 
rinsings  with  CCl4,  the  slide  was  placed  under  the 
microscope and particles were measured by using 100X 
magnification with oil immersion method. At least 100 
particles  in 25  different fields  were measured.  Results 
were reported as number of particles equal to 3 µm and 
those greater than and in between 3 to 5 µm. 
 Flame extension test: Metered dose inhalers were held 
at a distance of 18 cm from the flame of candle. They 
were sprayed for 15-20 seconds and flame extension was 
measured with help of a ruler.
[8]  
 Leak  test:  Metered  dose  inhaler  containers  were 
weighed and inserted in water bath, maintained at 50ºC. 
After  equilibration,  containers  were  checked  for 
presence of leaks in the form of air bubbles arising from 
orifice  or  valve  crimp.  These  containers  were  wiped 
clean with a tissue paper and their weights were recorded 
(W1). The containers were kept in upright position for 3 
days and were weighed at the end  of third  day (W2). 
Leakage rate was calculated as: 
Leakage rate: 365*24/ T (W1-W2), Where T= Time in hrs
 Vapour  pressure:  Vapour  pressure  was  measured  by 
means  of  ‘Comes  Pressure  gauge’  and  average  of  six 
readings was recorded.
Quantitative tests for metered dose inhalers
 Average weight per metered dose: Canisters were first 
detached from the adaptor body and their weights were 
determined. The first five sprays were fired in air and 
were referred to as ‘Test Firing’. After the test fire, the 
canisters were thoroughly wiped with a tissue paper and 
their  weights  were  recorded  (W1).  Five  successive 
deliveries were sprayed from the inhaler after placing the 
canisters  back  in  their  actuators.  The  canisters  were 
subsequently  removed  from the  adaptor  and  the  valve 
stem and orifice were wiped clean. The containers were 
weighed again and their weights were recorded (W2). 
Avg weight per metered dose = (W1-W2)/5
 Content per spray: The container was supported inside 
a beaker containing 75 ml of distilled water. Individually 
10  doses  were  delivered  inside  distilled  water  with 
intermittent shaking for 5 seconds after each actuation. 
These solutions were introduced into 100 ml volumetric 
flasks and were diluted to 100 ml with distilled water. 10 
ml  of  above  solutions  were  transferred  to  25  ml 
volumetric flasks to which 1 ml of 4-aminoantipyrine, 2 
ml of potassium ferricyanide, 1 ml of sodium carbonate 
were added and volume was made to 25 ml with distilled 
water and the absorbance was recorded at 505 nm using 
V-550 JASCO U.V/Vis spectrophotometer.
 Retention on adaptor: Amount retained on the adaptor 
represented the wasted drug which was not available for 
inhalation and should be restricted to minimum. Initially 
10 deliveries were fired in the exhaust. The components 
of MDI were separated and washed with the collecting 
liquid (distilled water). After through rinsing of canister, 
valve, adaptor, orifice and mouthpiece, the solution was 
collected in a 100 ml volumetric flask and analyzed for 
the content of active ingredient retained on the adaptor. 
 Content  uniformity: The  uniformity  of  content  of 
active ingredient in 10 doses was determined using the 
method similar to that mentioned in the content per spray 
test for MDI’s. In order to check extent of variation, 1
st, 
25
th, 50
th, 100
th, 150
th, 200
th, 225
th doses sprayed from 
the  device  were  analyzed  for  the  content  of  active 
ingredient in each spray.
In-vitro drug deposition studies
Pulmonary deposition pattern of the developed formulations 
was determined using two different impactor apparatus i.e. 
Twin impinger apparatus (Copley Scientific  Ltd, U.K) and 
Multistage  Anderson  Cascade  Impactor  (Type  ACI-MDI 
1000, Erweka)
 Twin  impinger: The  two  collecting  chambers  were 
filled with required amount of distilled water (7 ml in 
stage Ι and 30 ml in stage ΙΙ). MDI was attached to the 
device by a rubber collar and 10 sprays were fired into 
the apparatus. Side arm tube was connected to vacuum 
pump with flow rate of 60 l/min  which mimicked the 
respiratory  flow  in  normal  patients.  Gap  of  5 seconds 
was maintained between two successive sprays and MDI 
was thoroughly shaken before each spray was fired.  The 
reservoirs were rinsed with distilled water and amount of Bajaj et al. / Metered Dose Inhalation Formulations of Salbutamol Sulphate…..……
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drug  deposited  on  adaptor,  valve  and  collar  (Device, 
Stage Ι and stage ΙΙ) was determined. The deposition of 
drug  at  the  device  represented  the  non-respirable 
fraction.  
[9-10]
 Anderson  cascade  impactor: Eight  perforated  plates 
were arranged in ascending order of their diameter with 
‘0
th’  plate  on  the  top  and  ‘7
th’  plate  on  the  bottom. 
Cascade  impactor  plates  were  placed  below  each  of 
these and the base plate was connected to vacuum with 
flow rate of 28.3 l/min. An induction port was connected 
to the top of the impactor. The metered dose inhaler was 
attached to the device by means of rubber collar. Exactly 
10 sprays were fired in a manner similar to that for twin 
impinger. Each plate was rinsed with distilled water and 
amount of drug deposited on each plate was determined. 
Deposition of drug from stage 2 to filter was termed as 
“Respirable fraction”.
[11]
Evaluation of effect of adaptor and metering valve design 
on performance of the formulation
Adaptor A with orifice diameter of 0.48 mm and adaptor B 
with orifice diameter 0.33 mm were chosen for the study and 
drug  deposition  from  the  optimized  formulation  F1  was 
compared. Metering valves of 63 µl capacity obtained from 
two companies ‘Beespak’ and ‘Valois’ were coded as V1 and 
V2  respectively.  The  effect  of  metering  valve  was studied 
using  different  quality  control  tests  like  spray  pattern, 
average wt per metered dose and content per spray.
Stability studies
Formulation F1 was kept at 8°C, room temperature and 40°C 
for a period of three months. Chemical stability was assessed 
by monitoring the percent drug remaining in the formulation. 
Physical stability of the formulation was evaluated based on 
pH, vapour pressure, particle size distribution, leakage rate, 
redispersibility and average weight delivered per actuation.
Comparison of CFC and non-CFC formulations
Salbutamol  sulphate  formulation  F1  was  compared  with 
marketed  CFC  (C1)  and  non-CFC  (H1)  formulations.  The 
formulations  were  compared  with  respect  to  their  spray 
pattern,  particle  size  distribution,  vapour  pressure,  content 
uniformity and drug deposition pattern.
Table 1: Composition of developed Salbutamol sulphate formulations
Ingredients (g)
Formulations
F1 F2
Salbutamol sulphate equivalent to Salbutamol 0.020 0.020
95% Ethanol 2 4
Oleic acid 0.004 0.004
Tetrafluoroethane (HFA-134a) 15 15
RESULTS AND DISCUSSION
Salbutamol suspension formulations were prepared using 4 
mg of oleic acid as the surfactant and 2-4 gm of 95% ethanol 
as  the  co-solvent  (Table.1).  Developed  formulations  were 
subjected  to  various  qualitative  tests  to  ensure  proper 
performance  of  the  final  package  (Table.2).  Spray  pattern 
indicated  output  droplet  distribution  pattern  and  was  an 
important  parameter  for  evaluating  valve  and  actuator 
performance. The average diameter of the spots were found 
to be 1.5 cm for  both F1 and F2 indicating similar  output 
droplet  sizes  for  both  the  formulations.  Particle  size 
distribution governs the deposition of emitted dose from MDI 
and  hence  its  therapeutic  performance.  From  particle  size 
distribution data, it was seen that for F1 formulation most of 
the particles i.e 96-97% were less than 3 µm in diameter but 
in  case  of  formulation  F2  only  90%  particles  were  below 
3µm.  Thus, formulation F1 would provide better pulmonary 
deposition as compared to F2. The results of flame extension 
test  indicated  that  the  formulations  were  non-flammable. 
Results of leak test showed no change in weight indicating 
that  the  formulations  F1  and  F2  were  leak  proof.  Proper 
development of pressure inside the canister was essential so 
that desired  quantity of the contents are propelled into the 
metering valve and expelled  outside as fine spray.
[12] The 
internal   pressure was found to be in suitable range of 70-80 
psi for both F1 and F2 formulations. 
Several quantitative tests were conducted on the developed 
formulations (Table 3 and  Fig.1). It was observed that the 
average  weight delivered per metered dose was 76 mg for 
both the  formulations  indicating  effectiveness  of  the  valve 
system in delivering reproducible amount of formulation per 
actuation.  The content per actuation of the valve for both the 
formulations  was  found  to  be  within  the  pharmacopoeial 
limits as per the test in I.P 1996 (NLT 80% of the label claim 
and  NMT  120  %  of  the  label  claim).  Formulation  F1 
containing 2 ml of ethanol exhibited low standard deviation 
for most of the quantitative tests indicating better uniformity 
than formulation F2.
The  deposition  of  emitted  dose  was  a  critical  factor 
governing  the  therapeutic  efficacy  of  the  metered  dose 
inhalers.  This  test  was  performed  to  predict  the  in-vitro 
availability of active ingredient from the aerosolized product. 
As seen from Fig. 2, the net respirable fraction for F1 was in 
the range of 34 to 36.7% while for F2 it was from 20-22%, 
indicating higher pulmonary deposition for formulation F1.
The  results  of  drug  deposition  studies  from  two  different 
adaptors A and B were as shown in Fig. 3. Net respirable 
fractions  for  Adaptor  A  were  35.97%  and  36.7%  and  for 
Adaptor  B  were 19.8%  and  26.2%  by  Twin  impinger  and 
Cascade impactor respectively. Hence, it was concluded that 
the formulation performance with Adaptor A was better as 
compared  to  adaptor  B  due  to  the  larger  pore  size  of  the 
former. The results of quality control tests for Valves V1 and 
V2  were  found  to be  comparable  indicating  that  both  the 
valves V1 and V2 were efficient with equivalent performance 
characteristics (Table.4).
Formulation  F1 was selected  for stability studies based  on 
initial results from quality control tests (Table 5). The content 
per actuation from formulation F1 stored at all temperatures 
was  found  to  be  within  the  pharmacopoeial  limits. 
Formulation  stored  at  room  temperature  showed  average 
content  per  spray  of  104.72%  while  at  8°C  and  40°C  it 
showed 104.83% and 104.42 % average content per spray. 
This indicated there was no degradation of the drug at all a 
storage  conditions.  The  results  of  particle  size  distribution 
studies  indicated  no  significant  change  at  all  storage 
conditions  indicating  absence  of  agglomeration  or  crystal 
growth. Optimum vapour pressure was maintained under all 
conditions.  Leakage  rate  was  within  the  pharmacopoeial 
standards  as  per  the  test  in  I.P  1996.  Average  weight 
delivered per dose was found to be 76.04, 76.01 and 76.05 
mg at 8ºC, R.T and 40ºC respectively indicating effectiveness 
of valve system in delivering reproducible amount of drug 
content throughout the storage conditions.
Comparative  data  of formulations  F1,  H1 and  C1  were as 
shown in Table. 6; Fig. 4 and 5. Particle size distribution and 
content per spray were comparable for all the formulations.Bajaj et al. / Metered Dose Inhalation Formulations of Salbutamol Sulphate…..……
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Table 2: Qualitative tests on Salbutamol sulphate formulations
Formul
ations
Spray Pattern± S.D Particle size distribution ± S.D Flame 
extension test Leakage rate Vapour 
pressure (psi) Avg diameter (cm) Description < 3µm 3-5 µm S.D
F1 1.5± 0.258 Round spot, distinct violet 
color 97 3 ±0.23 FE No change in weight 80-85
F2 1.5 ± 0.047 Round to oval spot, violet 
center 90 10 ±2.18 FE No change in weight 80-85
S.D: Standard deviation, FE: Flame extinguished
Table 3: Quantitative tests for developed formulations
Formulations Avg weight per metered dose (mg) Content per spray± S.D Retention on adaptor (%)± S.D
F1 76.0 103.96±1.49 10.25±0.1008
F2 76.1 101.85± 3.52 11.13±0.6071
S.D: Standard deviation
Table 4: Evaluation of metering valve performance
Metering valves
Spray pattern Avg wt per metered 
dose ± S.D
Content per spray ± 
S.D Avg diameter (cm) Description
V1 1.5 Round to oval spot with violet centre 76.46 ±0.254 104.64± 0.53
V2 1.5 Round to oval spot with violet centre 76.51± 0.249 104.96± 0.531
S.D: Standard deviation
Table 5: Stability testing
Tests
Stability temperature
8ºC Room temperature 40ºC
% Drug delivered per spray ± S.D 104.83±0.935 104.72±0.872 104.42±0.986
pH range 5-6 5-6 5-6
Vapour pressure (psi) 80-85 80-85 80-85
Particle size distribution < 3 µm 96.2 96.8 96.6
3-5 µm 2.8 3.2 3.4
Avg wt per metered dose (mg) ± S.D 76.041±0.051 76.012±0.032 76.051±0.0699
Leakage rate (%) 0.004 0.0039 0.0079
S.D: Standard deviation
Table 6: comparative evaluation of optimized and marketed formulations
Formulations
Spray Pattern± S.D Particle size distribution ± S.D Content per 
spray
Vapour pressure 
(bar) at 25°C Avg diameter (cm) Description < 3µm 3-5 µm S.D
F1 1.44 Round circular spot, violet color 96 4 0.28 104.60±2.897 5.7
H1 1.5 Round spot, dark violet center 97 3 0.26 105.27±2.309 5.7
C1 1.2 Round uniform spot, dark violet 
center 96.8 3.2 0.20 104.67±2.268 3.4
S.D: Standard deviation
Fig. 1: Content uniformity of Salbutamol sulphate MDI suspensions
Fig. 2: In-vitro drug deposition studies for developed formulationsBajaj et al. / Metered Dose Inhalation Formulations of Salbutamol Sulphate…..……
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Fig.  3: In-vitro drug deposition studies for different adaptors
Fig. 4: Content uniformity of optimized and marketed formulations
Fig. 5: In-vitro drug deposition studies of optimized and marketed formulations
Also, the uniformity of content  was maintained  for all the 
formulations  till  the  last  dose. Lesser  diameter  of  droplets 
delivered by C1 in case of spray pattern test was due to the 
low  vapour  pressure  of  propellant  P-12  used  in  that 
formulation. Net respirable fractions for all the formulations 
were around 36.9% indicating equivalent performance.
Metered  dose  inhalation  formulations  using  non-CFC 
propellant Tetrafluoroethane were developed and optimized.  
Metered dose inhalation formulations containing Salbutamol 
Sulphate  with Tetrafluoroethane were found to possess the 
desired properties as indicated by the results of qualitative 
and  quantitative  tests  and  in-vitro  drug  deposition  studies. 
The orifice diameter of the adaptor was found to have a great 
impact  on  net  respirable  fraction.  Tetrafluoroethane  based 
formulation  showed  equivalent  performance  characteristics 
in comparison with marketed formulations and could be used 
as an environment friendly substitute for CFC propellants in 
metered dose inhaler formulations.
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